Obese hypertensive (OH) patients carrying TCF7L2 alleles predisposing to type 2 diabetes (T2D) may have a further increase in 'cardiometabolic' risk; therefore, we studied 204 OH patients (o65 years old) without T2D and 222 unselected adults to verify TCF7L2 allele frequencies and investigate the metabolic phenotype. Allele and genotype distribution between OH patients and controls was not different, whereas OH patients with metabolic syndrome (MetS) had a higher frequency of allele X than those without MetS (66.2 vs 40%, P ¼ 0.006). TCF7L2 DG10S478 X and rs7903146 T alleles may identify OH patients with further increased risk of developing T2D and DG10S478 X associated with, and may predispose OH to, MetS.
Type 2 diabetes (T2D) results from the interaction of environmental and genetic factors. Recently, Grant et al. 1 reported the association of transcription factor 7-like 2 (TCF7L2) variants with increased risk of T2D. DG10S478 microsatellite identifies a tetranucleotide repeat (TTTC) with six known alleles: allele 0 has five TTTC sequence repeats; all non-zero alleles express more than five repeats and are referred to as 'allele X'. Two SNPs (single-nucleotide polymorphisms), rs12255372 and rs7903146, were in strong linkage disequilibrium (LD) with DG10S478 and showed similarly robust associations with T2D. Subsequent papers reported that rs7903146 T allele had the strongest association with T2D and was more reliable across different populations. [2] [3] [4] [5] Haplotypes carrying rs7903146 T conferred similar risk regardless of whether they carried DG10S478 X or rs12255372 T, 4 suggesting rs7903146 T as either the risk variant itself or its closest known correlate.
Interestingly, the association between rs7903146 T and T2D was independent of body mass index (BMI), probably because TCF7L2 is involved in blood glucose homeostasis through regulation of insulin secretion from pancreatic b-cells, 6 without affecting insulin sensitivity.
Nevertheless, the majority of diabetic patients are obese and the risk of developing T2D increases with BMI. Because insulin resistance is one of the main mechanisms underlying T2D, it is not surprising that obesity, T2D and hypertension often coexist and cluster in the metabolic syndrome (MetS). Thus, an obese hypertensive (OH) patient has a high cardiovascular risk, and the onset of T2D increases it with a multiplicative effect. How many OH patients without diabetes carry a T2D-predisposing TCF7L2 variant? This study aimed at verifying DG10S478 X and rs7903146 T frequency in non-diabetic OH patients compared with a general young population. Moreover, we investigated the phenotype of OH patients carrying T2D-predisposing alleles and the presence of MetS.
The study was approved by the Local Ethics Committee. We recruited 204 consecutive nondiabetic OH patients (aged p65 years) referred to our Hypertension Centre. Obesity was defined as BMI X30 kg m À2 . Hypertension was defined as systolic blood pressure X140 mm Hg and/or diastolic blood pressure X90 mm Hg or current antihypertensive therapy. T2D was excluded on the basis of fasting glucose o100 mg per 100 ml or a negative 2 h oral glucose tolerance test when clinically indicated. Patients taking antidiabetic drugs or insulin were excluded and only women after the menopause were included. MetS was defined in accordance with the Adult Treatment Panel III criteria; 7 for 27 patients, diagnosis of MetS has not been possible because of missing data. A subgroup of 222 unselected participants in the Ancona Heart Doctors Study 8 constituted the general control population of similar ethnic background. In OH patients, blood was drawn after an overnight fast to measure glucose, creatinine, triglyceride, total and highdensity lipoprotein cholesterol levels; glomerular filtration rate was calculated according to the Modification of Diet in Renal Disease Study (MDRD) equation.
Genotyping for DG10S478 was carried out by PCR (using 5 0 -TTCAGGCCATTGGTGTTGTA-3 0 and 5 0 -AAAGTTCCCACCATCCCACT-3 0 as forward and reverse primers, respectively) and automated capillary sequencing. The rs7903146 polymorphism was genotyped using a TaqMan SNP Genotyping Assay (C_29347861_10; Applied Biosystems, Foster City, CA, USA).
Allele and genotype distribution between OH patients and controls, and deviation from the Hardy-Weinberg equilibrium (HWE) were tested with w 2 test. LD between rs7903146 and DG10S478 (the latter treated as biallelic marker) was assessed using Haploview 4.0. Analysis of variance adjusting for covariates was used to compare clinical and laboratory variables across genotypes. Bonferroni's method was used to correct for multiple genetic testing. The unadjusted OR (odds ratio) for MetS in subjects carrying T2D-predisposing TCF7L2 alleles was calculated. For DG10S478, the association was confirmed by logistic regression. Statistical analysis was performed with SPSS 13.0. A level of Po0.05 was considered as significant. Table 1 shows clinical characteristics of participants and genotype and allele frequency of genetic markers. HWE was respected for rs7903146 (P ¼ 0.24), while it was not suitable for DG10S478 because 'allele X' is composed of multiple alleles. However, the two markers were not in LD: D 0 was 0.47 (r 2 ¼ 0.22) in total population, 0.63 (r 2 ¼ 0.36) in controls and 0.34 (r 2 ¼ 0.10) in OH patients. In our population, rs7903146 T prevalence was slightly higher than in previous studies (30.7%). 4 There was no difference in allele and genotype distribution in OH patients compared with controls. There was no relationship between rs7903146 and clinical and laboratory variables or MetS.
DG10S478 allele X frequency was slightly higher than in the original cohorts (31.2%).
1 There was no difference in allele and genotype distribution in OH patients compared with controls, in whom there was no difference in clinical variables across genotypes. However, OH carrying DG10S478 X had higher BMI (35.1 (0.4) vs 33.7 (0.5), P ¼ 0.028) and a trend towards higher fasting glucose (93.6 (1.2) vs 89.7 (1.6), P ¼ 0.05). After Bonferroni's correction significance of such associations was lost. However, OH with MetS (n ¼ 142) had higher prevalence of allele X (66.2%) than those without MetS (n ¼ 35; allele X 40%). DG10S478 X conferred an unadjusted risk for MetS of 2.94 (95% CI (confidence intervals): 1.37-6.28, P ¼ 0.006). In logistic regression model including age, gender, BMI and rs7903146, the risk of MetS increased (OR 3.25, 95% CI: 1.43-7.4, P ¼ 0.005).
TCF7L2 variants are the most powerful known genetic markers for the risk of developing T2D, but they have never been investigated in non-diabetic OH patients who have high risk to develop T2D. We found no difference in T2D-predisposing allele prevalence between OH patients and the general, young control population. A larger and older Italian population showed similar rs7903146 T prevalence, 9 whereas general French population and controls in previous studies showed lower frequency (29.7%). 1, 4, 10 However, DG10S478 X prevalence is unknown in general Italian population and was lower in controls of the original cohort (26.6%). 1 Although prevalence of these alleles are not increased, OH carrying TCF7L2 X or T allele are likely to be at particularly high risk of developing T2D. In such patients, these markers can identify a subgroup at such level of 'cardiometabolic' risk that an aggressive approach with lifestyle modification plus pharmacological intervention is warranted.
Increasing evidence suggest that rs7903146 T predisposes to T2D by inducing a defect in insulin secretion and without affecting insulin sensitivity. 9, 11, 12 Actually, rs7903146 T explains mainly T2D cases in non-obese subjects 3,10 and a negative relationship with BMI was found. [2] [3] [4] 11 Thus, the absence of relationship between the rs7903146 polymorphism and clinical and laboratory values is not surprising in our OH patients, who are likely to be insulin resistant. In contrast, OH carrying DG10S478 X showed increased BMI and a trend towards higher fasting glucose than non-carrier subjects. Despite the loss of significance of these associations after Bonferroni's correction, this allele was more frequent among OH with MetS than those without and conferred an almost threefold risk of MetS in both unadjusted and adjusted (age, gender, BMI and the non-linked rs7903146) models. DG10S478 X and rs7903146 T have been reported to be in strong (r 2 ¼ 0.78) LD, 1 but it has not been confirmed in our population (r 2 ¼ 0.22), especially in OH patients (r 2 ¼ 0.10). Indeed, they appear to segregate into different haplotypes. 4, 12 HapB, that is specifically related to rs7903146 T, shows no or negative association with BMI, whereas HapA associates with obesity, 4 but it is unclear whether it associates with developing T2D.
11 Therefore, it cannot be excluded that the DG10S478 microsatellite marker associates with BMI and MetS through LD with another gene variant yet unidentified. Alternatively, the 'metabolic' effect of the allele X might require a specific phenotype (like obesity and hypertension) to be clinically evident. Thus, these two markers could indicate distinct routes (insulin resistance and impaired insulin secretion) towards a common end, that is, T2D.
Of course, 204 OH patients are not the 'ideal' large number for an association study. Nonetheless, we genotyped a well-characterized and phenotypically homogeneous population with increased 'cardiometabolic' risk probably through insulin resistance. Only few studies considered obese insulin-resistant patients as target population 2, 3 and none investigated OH patients, in whom genetic background seems to be peculiar.
In conclusion, TCF7L2 rs7903146 T allele is present in OH patients as much as in the general population and may usefully identify a subset of patients with especially high risk of developing T2D. However, DG10S478 X allele may predispose to MetS and, perhaps, T2D when obesity and hypertension coexist.
